Skip to content

Better Formulation. Better Delivery. Better Biologics

3-4 November 2026 Radisson Blu Hotel, London Heathrow, London, United Kingdom
Co-located Events
BioManUK2026 logo white
BioSourceEurope2026 logo white

KEY THEMES & TOPICS

Novel Formulation Strategies for Complex Biologics - mAbs, Bispecifics, & ADCs
Adjuvants & Immunostimulatory Technologies - Amplifying Vaccine Potency
Formulation Supply Chain – From Clinical to Commercial
From Formulation to Device Integration
LNP & RNA Formulation
Smart Aseptic Fill–Finish
WHO

For biopharma biotech and pharmaceutical leaders across Europe working in RNA design vaccine R&D biologics formulation drug delivery and stability science. This includes R&D Drug Product Analytical Development, CMC, Quality, Manufacturing professionals from leading pharmaceutical companies innovative biotechs, CDMOs, technology providers, and academic & research institutions.

WHAT
 A strategic platform dedicated to advancing the next generation of biologics formulation, stability, and delivery. BioFormulate Live 2026 unites three concurrent scientific streams - RNA Therapeutics, Vaccine Innovation, and Biologics Formulation & Delivery, offering deep technical insights spanning early development through to commercial-scale production. 
WHY
 To accelerate innovation in biologics drug development by bringing together top scientific, technical, and regulatory experts. Attendees gain practical solutions to stability challenges, formulation optimisation, patient-focused delivery, and manufacturing scale-up. The event enables high-value collaboration, technology discovery, and future-focused insights at the junction where formulation science meets global healthcare impact. 
icons cgw welcome_1
0 +

Senior Attendees

 Meet a concentrated audience of biologics RNA and vaccine development leaders from global pharma biotechs CDMOs and academia. 
icons cgw welcome-02
0 +

Expert Speakers

 Hear from world class leaders in RNA engineering formulation science structural biology vaccine innovation and drug product development. 
bwd2026-company-ezgifcom-speed.bb78342dfc94
0 +

Companies Represented

 A pan European gathering representing biopharma technology providers regulatory bodies and academic institutions. 

AGENDA AT A GLANCE

Day 1 | 3 November 2026
Novel Formulation Strategies for Complex Biologics - mAbs, Bispecifics, & ADCs
Networking Break
Adjuvants & Immunostimulatory Technologies - Amplifying Vaccine Potency
Lunch
Formulation Supply Chain – From Clinical to Commercial
Downstream Purification Optimisation
Networking Break
Strategies For Selecting & Managing CDMOs
Industry Roundtables
End of Conference Day 1
Day 2 | 4 November 2026
From Formulation to Device Integration
AI Driven Manufacturing
Networking Break
Next-Generation Therapeutics: RNA, Formulation & Process Innovation
Lunch
Smart Aseptic Fill–Finish
Panel Discussion - The Future of Biopharma Supply Chains – Building Resilience, Agility & Sustainability
Networking Break
Closing Panel Discussion: Future of European Biomanufacturing
End of Conference
DAY 1
3 November 2026
VIEW DAY 1 VIEW DAY 2
08:00 Registration & Coffee
08:50

Chairman’s Welcome Address

Harsha Reddy Group Lead - Head Upstream Process Development, CMC Bioprocess Lead, Accord BioPharma, UK
Novel Formulation Strategies for Complex Biologics - mAbs, Bispecifics, & ADCs
09:00

Advanced Formulation Strategies for Complex Biologics: mAbs, Bispecifics & ADCs

  • How dripping can impact filling process control
  • Reported approaches to avoid dripping in a filling process
  • Droplet elongation rate as an indicator of solution propensity for dripping
  • Impact of surfactants on solution propensity for dripping at the nozzle tip end
Sébastien Dasnoy Principal Scientist, Injectable Formulation Development, UCB, Belgium
09:25

Crack the Protein Formulation Code with Aunty

  • Protein formulation labs face challenges every day: more samples to test, increasingly complex candidates, and shorter timelines.
  • Optimizing stability, manufacturability, and developability requires extensive excipient screening across multiple parameters—all in less time than ever before.
  • This talk shows how you can use Aunty to speed up formulation studies from weeks to days using high-throughput, multi-attribute characterization in a 96-well SBS-format quartz plate.
  • By combining full-spectrum DSF, SLS, and DLS in a single experiment, you can gather all the melting and aggregation data necessary to make faster, more informed decisions while improving efficiency.
  • Automation-ready workflows keep grinding out results long after you’ve called it a day.
  • We’ll review a DoE-based excipient screen of three antibodies and an enzyme that identified major stability drivers in a single experiment.
  • We’ll also peek into colloidal parameters kD* and B22*, as well as freeze/thaw performance to provide a more complete picture of formulation behavior.
Solution Provider
Andre Mueller Director of Product Management, Unchained Labs, USA
09:50

From Bioprocess to Formulation: Building Robust and Scalable Strategies for Complex Biologics

  • Bridging upstream and downstream bioprocessing with formulation development to ensure product quality and stability. 
  • Addressing aggregation, viscosity, and stability challenges in complex biologics. 
  • Optimising process robustness, scalability, and manufacturability from clinical to commercial production. 
  • Integrating process development, formulation, and CMC strategies to accelerate commercial readiness.
Harsha Reddy Group Lead - Head Upstream Process Development, CMC Bioprocess Lead, Accord BioPharma, UK
10:15

Cracking Long-Acting Injectables Translation: Lessons from Small Molecules, Implications for Biologics

  • Early PK and biocompatibility data for small‑molecule LAIs often fail to predict clinical outcomes, creating a persistent predictability gap.
  • The injection site acts as a complex, dynamic system, where depot behavior, tissue response, and absorption are tightly linked.
  • Traditional approaches (e.g., IVIVC) are insufficiently predictive, requiring a shift to mechanistic, model‑informed translation.
  • Success depends on integrated CMC–PK–clinical strategies that reduce uncertainty early through coordinated design.
  • These learnings are relevant to high concentration /complex biologics, where greater molecular complexity further tightens the link between formulation, delivery, and clinical performance.
Marieta Duvnjak Head Science & Operations in Analytical Research and Development, Novartis, India
10:40 Networking Break
Adjuvants & Immunostimulatory Technologies - Amplifying Vaccine Potency
11:10

The CMC Leader Driving Vaccines from Development to Real-World Supply

  • Why scientific innovation alone is not enough to ensure successful vaccine or biologics commercialization
  • Identifying future CMC challenges before they become development bottlenecks
  • Designing products for manufacturability, affordability and sustainable global supply
  • The role of strategic CMC leadership in driving vaccines from development to real-world supply
Christine Hägglund VP CMC Development, Scandinavian Biopharma, Sweden
11:35

Workforce Value-at-Risk: Quantifying Talent Risk Across Biopharma Development and Manufacturing

  • Identifying critical workforce gaps and talent shortages across biopharma R&D, process development, and manufacturing. 
  • Quantifying the impact of workforce risks on productivity, operational efficiency, and manufacturing continuity. 
  • Developing data-driven strategies to assess skills gaps, workforce readiness, and future talent requirements. 
  • Building resilient talent pipelines through strategic workforce planning, upskilling, and cross-functional collaboration.
Dr Jason Beckwith SVP Talent Science & Thought Leadership, BioTalent, UK
12:00

Advancing Cancer Immunotherapies from Discovery to Clinical Development: Aligning Innovation, Formulation, and Patient Impact

  • Avancing an active immunotherapy for melanoma (iSCIB1+) from early- to late-phase clinical development 
  • Aligning formulation, CMC, and manufacturing strategies to support clinical progression 
  • Leveraging translational insights to establish a robust potency assurance strategy
  • Harnessing the advantages of DNA plasmid formulations to maximise patient outcomes
Callum Scott Senior Vice President, Development, Scancell, UK
12:30 Lunch
Formulation Supply Chain – From Clinical to Commercial
13:30

Strengthening Cold Chain and Distribution Strategies for Complex Biologics and Advanced Therapies

  • Ensuring end-to-end cold chain integrity for biologics and advanced therapies through robust temperature monitoring and control systems
  • Mitigating distribution risks for temperature-sensitive products via real-time tracking, data visibility, and contingency planning
  • Optimizing global logistics networks to support timely, compliant, and scalable delivery of complex therapies
  • Strengthening collaboration across supply chain stakeholders to maintain product quality from manufacturing to patient delivery
Kellen LaVigne Director, Supply Chain & Logistics, Aurion Biotech, USA
13:55

Implementing an Innovative Automated Tool to Speed Up Quality Assessments of Clinical and Commercial Drug Product Excursions Globally

  • Managing Excursions to Protect Quality and Supply
  • Automating Quality Impact Assessments
  • Turning Stability Data into Decision Support
  • Enabling Consistent Global Implementation
  • Reducing Assessment Time by Approximately 50%
Paul de Goede Principal Scientist Formulation Development, Johnson & Johnson Innovative Medicine, Netherlands
Downstream Purification Optimisation
14:20

Bispecific Purification: Double Trouble or Twice as Nice?

  • Tackling complex product-related impurities in bispecific purification  
  • Impact of molecular design, clone selection and analytics on manufacturability  
  • Developing robust, scalable purification strategies for next-generation bispecifics  
  • Industrial case studies and key lessons learned 
Gavin Wild Head of Early Process Sciences, UCB, UK
14:45 Networking Break
Strategies for Selecting & Managing CDMOs
15:00

Partnering for Success: Integrating Internal Expertise with External Manufacturing Capabilities

  • CDMO selection process, relationship management
  • An example of what can be achieved when both parties are aligned on a shared vision.
Franz Schnetzinger VP / Head PAD & QC, AAVantgarde Bio, UK
15:25

Managing CDMO Partnerships Across Formulation & Supply Networks (TBC)

  • Selecting the right CDMO partners for formulation development, manufacturing, and commercial supply.
  • Establishing governance models that drive performance, transparency, and long-term collaboration.
  • Managing supply chain risks, capacity constraints, and business continuity across external networks.
  • Using performance metrics and operational reviews to ensure quality, reliability, and on-time delivery.
Karen O'Hanlon Chief Operating Officer, StablePharma, UK
15:50

Choosing the Right Outsourcing Partner: From Payload to Fill-Finish

  • Evaluating CDMO capabilities across the full manufacturing workflow
  • Strengthening collaboration and oversight across multi-partner supply chains
Abisola (Abi) Kuforiji Associate Director-External Manufacturing -Operations lead (EMEA), MSD, Switzerland
16:05
Roundtable Discussion

AI in Supply Chain - Are they dependable for decisions?

Niveth Richard Supply Chain Decision Intelligence Lead, GSK, UK

Scaling Biologics Manufacturing for Future Demand

Dirk Boehm Site Head DS Penzberg (VP), Roche, Germany

Maximising Drug Product Manufacturing

Alexander Hempel Director Manufacturing, Avethera, Germany

Securing Biomanufacturing Supply Chains: Innovative Approaches to Accessing Critical Materials and Consumables (LMICs approach)

Valerie Chambard-Benalleg Manufacturing Supply Chain Lead, CEPI, UK

The Outsourcing Paradox: Preserving Bandwidth Without Losing Scientific Expertise and Strategic Control

Julia Hinteramskogler Head of Technical Development, Elaris, Austria

Building High-Trust Sponsor-CDMO Relationships

Franz Schnetzinger VP / Head PAD & QC, AAVantgarde Bio, UK

Formulation as a Commercial Differentiator

Marco Carfagna Head of Formulation Development & Drug Product Labs, Formycon, Germany
17:05 Key Takeaways
17:05 Cocktail Reception
18:00 End of Conference Day 1
DAY 2
4 November 2026
VIEW DAY 1 VIEW DAY 2
08:00 Registration & Coffee
08:50

Chairman’s Welcome Address

Sarah Pasqualinotto External Site Lead, External Operations (Associate Director), Biogen, Switzerland
From Formulation to Device Integration
09:00

Bridging Formulation, Manufacturing, and Process Development in Advanced Cell Therapies

  • Integrating formulation, process development, and manufacturing to ensure consistent quality in advanced cell therapies
  • Overcoming scale-up and variability challenges while maintaining cell viability and functional potency
  • Developing closed, automated, and scalable processes to enable robust and reproducible cell therapy production
  • Aligning cross-functional teams early to streamline tech transfer
Hollie Bartley Director, Process Development, Resolution Therapeutics, UK
09:25

Nebulized IgG: A Combination Product Odyssey

  • Phase appropriate solutions
  • Innovation: Balancing development speed with program risk
  • Combination product mind set: The whole is greater than the parts
Max Corbett Senior Director, CMC Group Head Biologics and Small Molecule, CSL, Switzerland
09:50

CMC at the Board Table: Connecting Technical Development with Biotech Strategy

Julia Hinteramskogler Head of Technical Development, Elaris, Austria
AI Driven Manufacturing
10:15

A Digital Future for CMC: Modelling and AI

  • Digital innovation in the development and manufacture of medicines
  • Models in pharmaceutical development and manufacturing
  • Evolution of the regulatory framework for model-based controls
  • AI in CMC development and manufacture
  • Overcoming barriers to implementation and organisational readiness
  • Lessons learned from integrating emerging technologies into development and manufacturing
Tejash Shah Senior Director, Biopharm CMC Regulatory Affairs, GSK, UK
10:40 Networking Break
Next-Generation Therapeutics: RNA, Formulation & Process Innovation
11:10

The Controlled Temperature Chain and Lyophilised RNA Vaccines

  • The motivation for producing lyophilised RNA vaccines 
  • Lipid nanoparticle formulations of mRNA and saRNA that are suitable for freeze-drying 
  • Parameters used to identify the formulation space and process analytical technology 
  • Physico-chemical characterisation and bioassay 
  • Early stability study read-outs. 
Dr Christopher van der Walle Head of Formulation Science, MHRA, UK
11:35

Turning Junk into Gems: Long Non-Coding RNAs Unlock New Therapeutic Horizons?

  • Overview of the non-coding field 
  • Non-coding elements as novel pharmacological targets
  • Developing a technological pipeline for identificaiton and validation of non-coding pharmacological targets 
  • RNA therapeutics targeting non-coding elements 
Alessandro Bonetti Director, AstraZeneca, UK
12:00

New Strategies for Oral Delivery of Biologics

  • Overcoming gastrointestinal barriers, enzymatic degradation, and poor absorption to improve oral bioavailability of biologics. 
  • Exploring innovative formulation approaches, including nanoparticles, permeation enhancers, and protective delivery systems. 
  • Advancing targeted intestinal delivery and absorption technologies to improve therapeutic efficacy and patient convenience. 
  • Addressing formulation stability, scalability, and clinical translation challenges in developing commercially viable oral biologics. 
Dr Driton Vllasaliu Reader in Biotherapeutics Delivery, King’s College London, UK
12:25 Lunch
Smart Aseptic Fill–Finish
13:30

From Tech Transfer to Commercial Supply: Ensuring Quality in Fill–Finish Operations

  • Ensuring seamless technology transfer from process development to commercial fill–finish manufacturing. 
  • Strengthening aseptic processing, contamination control, and sterility assurance to maintain product quality. 
  • Implementing robust process validation, quality control, and regulatory compliance strategies for commercial readiness. 
  • Optimising fill–finish operations through automation, risk management, and continuous process improvement to ensure reliable commercial supply. 
Sarah Pasqualinotto External Site Lead, External Operations (Associate Director), Biogen, Switzerland
13:55

From tech transfer to commercial supply, Digitalisation of the formulation, MSAT leadership in vaccines formulation fill and finish

  • Driving seamless technology transfer from vaccine formulation development to commercial fill–finish manufacturing. 
  • Leveraging digitalisation, automation, and real-time process monitoring to enhance formulation and manufacturing efficiency. 
  • Strengthening MSAT leadership in process optimisation, technology transfer, scale-up, and cross-functional collaboration. 
  • Ensuring product quality, sterility assurance, and regulatory compliance throughout vaccine formulation and commercial fill–finish operations. 
Laurent Marcellin Head of MSAT Vaccines, Takeda, Switzerland
14:15

Beyond OEE: Integrating Asset Excellence, Automation and Contamination Control in Pre-Filled Syringe Manufacturing

  • Enhancing asset reliability and operational efficiency beyond traditional OEE metrics. 
  • Leveraging automation and real-time monitoring to optimise manufacturing performance. 
  • Strengthening contamination control and sterility assurance in aseptic operations. 
  • Integrating predictive maintenance and digital technologies to improve quality and scalability.
Tarik Cheema Asset Excellence Lead Pre-Filled Syringes, Roche, Switzerland
14:40 Networking Break
14:55
Panel Discussion

The Future of Biopharma Supply Chains – Building Resilience, Agility & Sustainability

  • Resilience in an Increasingly Unpredictable World  
  • Data, AI & Digitalisation – Creating a More Intelligent Supply Chain 
  • From Development to Launch – Building Supply Readiness Earlier 
  • Building the Future Supply Chain – Scalability, Sustainability & Patient Access 
Moderator
Dr Christopher van der Walle Head of Formulation Science, MHRA, UK
Panellists
Christian Zimmer Executive Director, Head SUT & ADC Drug Substance Manufacturing, Roche, Switzerland Shyam Panjwani Senior Principal CMC Data Scientist, Bayer, USA Max Corbett Senior Director, CMC Group Head Biologics and Small Molecule, CSL, Switzerland Kellen LaVigne Director, Supply Chain & Logistics, Aurion Biotech, USA Kristin Grande Senior Manager, Technical Marketing - Life Sciences, Greenfield Global, USA
15:40
Panel Discussion

The Future of European Biomanufacturing: Capabilities, Competitiveness and Innovation

  • Biomanufacturing Beyond 2030: Future priorities and preparedness gaps
  • Europe’s Competitive Edge: Attracting development and manufacturing investment
  • Strategic Partnerships: Enabling scale-up while retaining critical in-house expertise
  • AI in Biomanufacturing: Opportunities, risks and implementation readiness
Moderator
Julia Hinteramskogler Head of Technical Development, Elaris, Austria
Panellists
Syed Saqib Naqvi Senior Manager, Digital Excellence, Amicus Therapeutics, UK Jose Martinez Calderon QA R&D and Commercial Product Development Senior Director, Almirall, Spain Michael Palige Process Development & CMC Lead, Takeda, Austria
16:15 Closing Remarks
16:45 End of Conference

MEET THE SPEAKERS

Filippo Ramondelli BIG PHARMA

Filippo Ramondelli

Associate Director - TT & Project Management Lead
Takeda
Italy
Connect on LinkedIn
Marcelo Castro BIG PHARMA

Marcelo Castro

Senior Director, Global Biopharma External Supply Operations Quality
Pfizer
Ireland
Connect on LinkedIn
Paul de Goede BIG PHARMA

Paul de Goede

Principal Scientist Formulation Development
Johnson & Johnson Innovative Medicine
Netherlands
Connect on LinkedIn
Tarik Cheema BIG PHARMA

Tarik Cheema

Asset Excellence Lead Pre-Filled Syringes
Roche
Switzerland
Connect on LinkedIn
Marieta Duvnjak BIG PHARMA

Marieta Duvnjak

Head Science & Operations in Analytical Research and Development
Novartis
India
Connect on LinkedIn
Max Corbett BIG PHARMA

Max Corbett

Senior Director, CMC Group Head Biologics and Small Molecule
CSL
Switzerland
Connect on LinkedIn
Sarah Pasqualinotto BIG PHARMA CHAIRMAN

Sarah Pasqualinotto

External Site Lead, External Operations (Associate Director)
Biogen
Switzerland
Connect on LinkedIn
Brendan Noone BIG PHARMA

Brendan Noone

Senior Director, Global Supply Chain & Strategy
AstraZeneca
Ireland
Connect on LinkedIn
BioUK2026_SPEAKER_Cathal Gallagher-1 BIG PHARMA

Cathal Gallagher

Senior Director-Head of Quality, External Operations EU
Takeda
Ireland
Connect on LinkedIn
BioUK2026_SPEAKER_Abisola (Abi) Kuforiji BIG PHARMA

Abisola (Abi) Kuforiji

Associate Director-External Manufacturing -Operations lead (EMEA)
MSD
Switzerland
Connect on LinkedIn
Sébastien Dasnoy

Sébastien Dasnoy

Principal Scientist, Injectable Formulation Development
UCB
Belgium
Connect on LinkedIn
Jose Martinez Calderon

Jose Martinez Calderon

QA R&D and Commercial Product Development Senior Director
Almirall
Spain
Connect on LinkedIn
Marco Carfagna

Marco Carfagna

Head of Formulation Development & Drug Product Labs
Formycon
Germany
Connect on LinkedIn
Harsha Reddy

Harsha Reddy

Group Lead - Head Upstream Process Development, CMC Bioprocess Lead
Accord BioPharma
UK
Connect on LinkedIn
Speakers_photo_foleon_Giorgio Salciarini

Giorgio Salciarini

Head of Sales - Technical Business Development
BSP Pharmaceuticals
Italy
Connect on LinkedIn
BioUK2026_SPEAKER_Kristin Grande-1

Kristin Grande

Senior Manager, Technical Marketing - Life Sciences
Greenfield Global
USA
Connect on LinkedIn

 Interested in Sharing Your Expertise and Insights? 

Sponsors & Media Partner

Special thanks to our event partners, without whom we would not be able to provide
this networking, learning, and collaborating platform to the community

Looking to partner with us for this event?

EXPECTED AUDIENCE SNAPSHOT
Biopharma & Biotech
Attendance from

Biopharma & Biotech

45%
Big Pharma
Attendance from

Big Pharma

30%
Technology Providers CDMOs and CROs
Attendance from

Technology Providers CDMOs and CROs

15%
Academic & Research Institutions
Attendance from

Academic and Research Institutions

10%

Decision Makers

Directors, Heads, Senior Managers
C-level, VPs, and Global Leads
Scientists, Researchers, and Technical Specialists

By Geography

map-bfl2026

By Profile

Formulation, Delivery & Stability
0%
R&D: Drug Product, RNA / Next-Generation Modalities
0%
Analytical Development & Characterisation
0%
CMC & Regulatory Affairs
0%
Supply Chain / Planning
0%
Manufacturing, Process Development & Scale-Up
0%

By Job Title

Directors & VPs of Formulation, Drug Product, R&D
0%
Heads of RNA Development
0%
Heads of Vaccine R&D
0%
Principal Scientists (Formulation & Biophysics)
0%
CMC Strategy Leaders
0%
Device & Drug Delivery Engineers
0%
Target Attendee Companies
Big Pharma
Biopharma
CDMOs

Targeted Attendees List

View Expanded List
SPONSORSHIP OPPORTUNITIES
Who Should Sponsor?

RNA Technology and Delivery Platform Providers

LNP and Non Viral Delivery Developers

Bioprocessing Equipment Manufacturers

CDMOs CMOs RNA vaccines biologics

Analytical and Characterisation Tool Providers

Drug Delivery Device Engineering Firms

Excipients and Raw Material Suppliers

Cold Chain Packaging and Fill Finish Solution Providers

Software Automation and AI Providers for Drug Product and Stability

Sponsorship_bwd2026_icon__0004

Thought Leadership Speaking

Sponsorship_bwd2026_icon__0003

Panel Participation

Sponsorship_bwd2026_icon__0002

Solution Showcases

Sponsorship_bwd2026_icon__0001

Engagement and Visibility Opportunities

Sponsorship_bwd2026_icon__0006

Branding and Digital Visibility

Sponsorship_bwd2026_icon__0000

Exclusive Networking

TESTIMONIALS
Speaker Headshot BWD2026 Heiner Apeler 2
Dr Heiner Apeler
VP Head of Biologics Development
Bayer Germany

The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.

BioOut2026_SPEAKER_John Bridgeman
John Bridgeman
CSO
Immunokey UK

Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey’s development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal. 

Speakers_photo_bwd_website_Dennis-Stelljes
Dennis Stelljes
Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing
BMS Switzerland

 Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I’m excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity! 

Speaker Headshot BWD2026 Andrew Kelly 2
Dr Andrew Kelly
Director, Manufacturing Technology
BMS Ireland

Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators 

Speakers_photo_bwd_website_Thomas-Villiger
Dr Thomas Villiger
Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW Switzerland

A fantastic deep dive into the DACH region’s CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together. 

Brian O'Connor | VP Global Quality, Orchard Therapeutics, UK
Brian O'Connor
VP Global Quality
Orchard Therapeutics UK

Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees. 

Alvaro Avivar-Valderas | Associate Director - Cell Therapy Technology & Product Engine, Takeda, Spain
Alvaro Avivar-Valderas
Associate Director - Cell Therapy Technology & Product Engine
Takeda Spain

Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!

Speaker Headshot BWD2026 Steffen Schulze 2
Steffen Schulze
Strategic Analytics & Business Analytics Lead
Roche Switzerland

I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants. 

merck200
Terry Gray
Field Marketing Manager
Merck

I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.

BioUK2026_SPEAKER_Dr Warren Roche
Warren Roche
Senior Statistical Expert
Sanofi Ireland

Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event 

BWD2026 Website Headshot Speaker Michael Inglis 2
Michael Inglis
Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease Ireland

Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event.

I hope we have opportunity to connect again in the future.

Speaker Headshot BWI2026 Shada Warreth 2
Shada Warreth
Global Partnerships Implementation Senior Manager
NIBRT Ireland

 Well done on a very informative and successful event.

 

TICKETS
Free_Ticket_Mockup_London BIOF26 BP Website
From £699 + VAT
Free_Ticket_Mockup_London BIOF26 SSP Website
From £2895 + VAT

VENUE

Radisson Blu Hotel, London Heathrow

140 Bath Road, Harlington, Hayes UB3 5AW, UK
Getting There Accommodation Options View the Floorplan

Travel Options

Travel options Radisson Blu Hotel, London Heathrow 140 Bath Road, Hayes, Middlesex, UB3 5AW
We look forward to welcoming you to our event at the Radisson Blu Hotel, conveniently located just minutes from Heathrow Airport. Please find travel guidance below to help you plan your journey. 
subway.286a621e9981

By London Underground

Take the London Underground Piccadilly Line toward Heathrow Airport.

  • Alight at Heathrow Terminal 2 & 3 Underground Station
  • From the station, the hotel is a short taxi or bus journey away

Estimated travel time: 45–60 minutes from central London.

bus.092fa764c07e

From Heathrow Airport

The hotel is located along Bath Road, with regular bus services connecting all terminals.

  • Local bus routes: 105, 111, 140, 285
  • Hotel Hoppa shuttle service also available
  • Alight on Bath Road, a short walk from the hotel

Estimated travel time: 10–20 minutes

taxi_2.75bc650d90cf

Taxi or Ride-Hailing

Taxis and ride-hailing services are readily available at all Heathrow terminals.

Estimated travel time: 5–10 minutes Estimated cost: £10–£20

car.e22d1548067f

By Car

The hotel is easily accessible by road:

  • Address: 140 Bath Road, Hayes, Middlesex, UB3 5AW
  • Located just off the M4 motorway
On-site parking is available at the hotel
train_2.c46ac37e7110

From Other UK Cities

For guests travelling from outside London:

  • Arrive at London Paddington Station
  • Continue via:
    • Heathrow Express (fastest option), or
    • Elizabeth line (cost-effective alternative)
  • Transfer to bus or taxi for the final leg

Accommodation Options

Explore recommended hotels near the venue.

Exclusive delegate hotel rate

Please note: the conference registration fee does not include hotel accommodation or travel expenses.

IMAPAC has secured an exclusive discounted room rate for conference delegates. Use one of the booking options below and quote the conference block code where applicable.

Please complete your booking by 03 October 2026 to secure the discounted conference rate. Bookings made after the cut-off date are subject to hotel availability and may be charged at the prevailing room rate.

Standard Double Room

  • Single occupancy£129.00
  • Double occupancy£139.00

Rates include full breakfast.

Call the Radisson Blu Hotel, London Heathrow at +44 (0)20 8759 6311 and quote the block code “BIOF021126”.

Option 2 – By Email

Email the Radisson Blu Hotel, London Heathrow Reservations Team at reservations.heathrow@radissonblu.com
and quote the block code “BIOF021126”.

Email Hotel
Radisson Blu Hotel, London Heathrow Venue Hotel Special Rate

Radisson Blu Hotel, London Heathrow

140 Bath Road, Hayes, Middlesex, UB3 5AW
venue for this event

 To book a room at this hotel, please click the button below 

Book a Room
accom 2

London Heathrow Mariott Hotel

Bath Road Heathrow, Airport, Hayes UB3 5AN
4 minute walk from venue

 To book a room at this hotel, please click the button below 

Book a Room
accom 3

Ibis Style London Heathrow Airport

272 Bath Rd, London UB3 5AY
8 minute walk from venue

 To book a room at this hotel, please click the button below 

Book a Room
accom 4

Premier Inn London Heathrow

15 Bath Rd, London TW6 2AB
5 minute drive from venue

 To book a room at this hotel, please click the button below 

Book a Room
Event venue floorplan

Virtual Tour of Commonwealth Suite Virtual Tour of the Atrium Virtual Tour of Royal Suite
Please find the booth allocation in the table below.
3 Briggs of Burton 4 Alfa Laval 7a MabPlex 7b Greenfield Global 8 BSP Pharmaceuticals 11 QuickSTAT 14 AsTec Chemicals 17 Unchained Labs 18 Kemwell Biopharma 19 Inprocess LSP